- Author: Pavani Chalasani, MD, MPH; Chief Editor: Jules E Harris, MD, FACP, FRCPC more...
Worldwide, breast cancer is the most frequently diagnosed life-threatening cancer in women and the leading cause of cancer death among women. See the image below.
See Cutaneous Clues to Diagnosing Metastatic Cancer, a Critical Images slideshow, to help identify various skin lesions that are cause for concern. Also, see the Breast Lumps in Young Women: Diagnostic Approaches slideshow to help manage palpable breast lumps in young women.
Signs and symptoms
Early breast cancers may be asymptomatic, and pain and discomfort are typically not present. If a lump is discovered, the following may indicate the possible presence of breast cancer:
Change in breast size or shape
Skin dimpling or skin changes
Recent nipple inversion or skin change, or nipple abnormalities
Single-duct discharge, particularly if blood-stained
See Clinical Presentation for more detail.
Breast cancer is often first detected as an abnormality on a mammogram before it is felt by the patient or health care provider.
Evaluation of breast cancer includes the following:
The following physical findings should raise concern:
Lump or contour change
Edema or peau d’orange
If a palpable lump is found and possesses any of the following features, breast cancer may be present:
Fixation to skin or muscle
Early detection remains the primary defense in preventing breast cancer. Screening modalities include the following:
Clinical breast examination
Magnetic resonance imaging
Ultrasonography and MRI are more sensitive than mammography for invasive cancer in nonfatty breasts. Combined mammography, clinical examination, and MRI are more sensitive than any other individual test or combination of tests.
Core biopsy with image guidance is the recommended diagnostic approach for newly diagnosed breast cancers. This is a method for obtaining breast tissue without surgery and can eliminate the need for additional surgeries. Open excisional biopsy is the surgical removal of the entire lump.
See Workup for more detail.
Surgery and radiation therapy, along with adjuvant hormone or chemotherapy when indicated, are now considered primary treatment for breast cancer. Surgical therapy may consist of lumpectomy or total mastectomy. Radiation therapy may follow surgery in an effort to eradicate residual disease while reducing recurrence rates. There are 2 general approaches for delivering radiation therapy:
External-beam radiotherapy (EBRT)
Partial-breast irradiation (PBI)
Surgical resection with or without radiation is the standard treatment for ductal carcinoma in situ.
Hormone therapy and chemotherapy are the 2 main interventions for treating metastatic breast cancer. Common chemotherapeutic regimens include the following:
Two selective estrogen receptor modulators (SERMs), tamoxifen and raloxifene, are approved for reduction of breast cancer risk in high-risk women.
In patients receiving adjuvant aromatase inhibitor therapy for breast cancer who are at high risk for fracture, the monoclonal antibody denosumab or either of the bisphosphonates zoledronic acid and pamidronate may be added to the treatment regimen to increase bone mass. These agents are given along with calcium and vitamin D supplementation.
Worldwide, breast cancer is the most frequently diagnosed life-threatening cancer in women. In less-developed countries, it is the leading cause of cancer death in women; in developed countries, however, it has been surpassed by lung cancer as a cause of cancer death in women. In the United States, breast cancer accounts for 29% of all cancers in women and is second only to lung cancer as a cause of cancer deaths. (For discussion of male breast cancer, see Breast Cancer in Men.)
Many early breast carcinomas are asymptomatic; pain or discomfort is not usually a symptom of breast cancer. Breast cancer is often first detected as an abnormality on a mammogram before it is felt by the patient or healthcare provider.
The general approach to evaluation of breast cancer has become formalized as triple assessment: clinical examination, imaging (usually mammography, ultrasonography, or both), and needle biopsy. (See Workup.) Increased public awareness and improved screening have led to earlier diagnosis, at stages amenable to complete surgical resection and curative therapies. Improvements in therapy and screening have led to improved survival rates for women diagnosed with breast cancer.
Surgery and radiation therapy, along with adjuvant hormone or chemotherapy when indicated, are now considered primary treatment for breast cancer. For many patients with low-risk early-stage breast cancer, surgery with local radiation is curative. (See Treatment.)
Adjuvant breast cancer therapies are designed to treat micrometastatic disease or breast cancer cells that have escaped the breast and regional lymph nodes but do not yet have an established identifiable metastasis. Depending on the model of risk reduction, adjuvant therapy has been estimated to be responsible for 35-72% of the decrease in mortality.
Over the past 3 decades, extensive and advocate-driven breast cancer research has led to extraordinary progress in the understanding of the disease. This has resulted in the development of more targeted and less toxic treatments. (See Treatment and Medication.)
The breasts of an adult woman are milk-producing glands on the front of the chest wall. They rest on the pectoralis major and are supported by and attached to the front of the chest wall on either side of the sternum by ligaments. Each breast contains 15-20 lobes arranged in a circular fashion. The fat that covers the lobes gives the breast its size and shape. Each lobe comprises many lobules, at the end of which are glands that produce milk in response to hormones (see the image below).
The current understanding of breast cancer etiopathogenesis is that invasive cancers arise through a series of molecular alterations at the cell level. These alterations result in breast epithelial cells with immortal features and uncontrolled growth.
Genomic profiling has demonstrated the presence of discrete breast tumor subtypes with distinct natural histories and clinical behavior. The exact number of disease subtypes and molecular alterations from which these subtypes arise remains to be fully elucidated, but these generally align with the presence or absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).
This view of breast cancer--not as a set of stochastic molecular events, but as a limited set of separable diseases of distinct molecular and cellular origins--has altered thinking about breast cancer etiology, type-specific risk factors, and prevention and has had a substantial impact on treatment strategies and breast cancer research.
Evidence from The Cancer Genome Atlas Network (TCGA) confirms the following 4 main breast tumor subtypes, with distinct genetic and epigenetic aberrations (see the image below):
It is noteworthy that the basal-like breast tumor subgroup shares a number of molecular characteristics common to serous ovarian tumors, including the types and frequencies of genomic mutations. These data support the evidence that some breast cancers share etiologic factors with ovarian cancer. Most compelling are the data showing that patients with basal-type breast cancers show treatment responsiveness similar to that of ovarian cancer patients.
The various types of breast cancers are listed below by percentage of cases:
Infiltrating ductal carcinoma is the most commonly diagnosed breast tumor and has a tendency to metastasize via lymphatics; this lesion accounts for 75% of breast cancers
Over the past 25 years, the incidence of lobular carcinoma in situ (LCIS) has doubled, reaching a current level of 2.8 per 100,000 women; the peak incidence is in women aged 40-50 years
Infiltrating lobular carcinoma accounts for fewer than 15% of invasive breast cancers
Medullary carcinoma accounts for about 5% of cases and generally occurs in younger women
Mucinous (colloid) carcinoma is seen in fewer than 5% of invasive breast cancer cases
Tubular carcinoma of the breast accounts for 1-2% of all breast cancers
Papillary carcinoma is usually seen in women older than 60 years and accounts for approximately 1-2% of all breast cancers
Metaplastic breast cancer accounts for fewer than 1% of breast cancer cases, tends to occur in older women (average age of onset in the sixth decade), and has a higher incidence in blacks
Mammary Paget disease accounts for 1-4% of all breast cancers and has a peak incidence in the sixth decade of life (mean age, 57 years)
Epidemiologic studies have identified a number of risk factors that are associated with an increased risk of a woman developing breast cancer. Several risk factors have been found to be clinically useful for assessing a patient’s risk of breast cancer. Many of these factors form the basis of breast cancer risk assessment tools currently being used in the practice setting.
Age and gender
Increasing age and female sex are established risk factors for breast cancer. Sporadic breast cancer is relatively uncommon among women younger than 40 years but increases significantly thereafter. The effect of age on risk is illustrated in the SEER (Surveillance, Epidemiology and End Results) data, where the incidence of invasive breast cancer for women younger than 50 years is 44.0 per 100,000 as compared with 345 per 100,000 for women aged 50 years or older.
The total and age-specific incidence for breast cancer is bimodal, with the first peak occurring at about 50 years and the second occurring at about 70 years. This bimodal pattern may reflect the influence of age within the different tumor subtypes; poorly differentiated, high-grade disease tend to occur earlier, whereas hormone-sensitive, slower-growing tumors tend to occur with advancing age.
Family history of breast cancer
A positive family history of breast cancer is the most widely recognized risk factor for breast cancer. The lifetime risk is up to 4 times higher if a mother and sister are affected, and it is about 5 times greater in women who have two or more first-degree relatives with breast cancer. The risk is also greater among women with breast cancer in a single first-degree relative, particularly if the relative was diagnosed at an early age (≤50 years). Despite a history indicating increased risk, many of these families have normal results on genetic testing.
A family history of ovarian cancer in a first-degree relative, especially if the disease occurred at an early age (< 50 years), has been associated with a doubling of breast cancer risk. This often reflects inheritance of a pathogenic mutation in the BRCA1 or BRCA2 gene.
The family history characteristics that suggest increased risk of cancer are summarized as follows:
Two or more relatives with breast or ovarian cancer
Breast cancer occurring in an affected relative younger than 50 years
Relatives with both breast cancer and ovarian cancer
One or more relatives with two cancers (breast and ovarian cancer or 2 independent breast cancers)
Male relatives with breast cancer
BRCA1 and BRCA2 mutations
Ataxia telangiectasia heterozygotes (quadrupled risk)
Ashkenazi Jewish descent (doubled risk)
A small percentage of patients, usually with a strong family history of other cancers, have cancer syndromes. These include families with a mutation in the PTEN, TP53, MLH1, MLH2, CDH1, or STK11 gene.
To aid in the identification of mutation carriers of BRCA1/2, a number of family history–based risk assessment tools have been developed for clinical use, including the following:
Myriad I and II
Ontario Family History Assessment Tool (FHAT)
All of these assessment tools are highly predictive of carrier status and aid in reducing testing costs for the majority of mutation negative families. BRCAPRO, the most commonly used model, identifies approximately 50% of mutation-negative families, avoiding unnecessary genetic testing, and fails to screen only about 10% of mutation carriers.
Notably, a significant portion of ovarian cancers not previously considered familial can be attributed to BRCA1 or BRCA2 mutations. This finding has led to the suggestion that women with nonmucinous invasive ovarian cancers may benefit from genetic testing to determine mutation status independent of a strong history or no history of breast cancer.
The National Institutes of Health (NIH) provides a Cancer Genetics Services Directory. This is a partial listing of professionals who provide services related to cancer genetics, including cancer risk assessment, genetic counseling, and genetic susceptibility testing.
Reproductive factors and steroid hormones
Late age at first pregnancy, nulliparity, early onset of menses, and late age of menopause have all been consistently associated with an increased risk of breast cancer.[9, 10, 11, 12, 13] Prolonged exposure to elevated levels of sex hormones has long been postulated as a risk factor for developing breast cancer, explaining the association between breast cancer and reproductive behaviors.[14, 15]
Clinical trials of secondary prevention in women with breast cancer have demonstrated the protective effect of selective estrogen receptor modulators (SERMs) and aromatase inhibitors on recurrence and the development of contralateral breast cancers. Use of SERMs in women at increased risk for breast cancer has prevented invasive ER-positive cancers.[17, 18, 19] These data support estradiol and its receptor as a primary target for risk reduction but do not establish that circulating hormone levels predict increase risk.
A number of epidemiologic and pooled studies support an elevated risk of breast cancer among women with high estradiol levels.[20, 21] The Endogenous Hormones and Breast Cancer Collaborative Group (EHBCG) reported a relative risk of 2.58 among women in the top quintile of estradiol levels.
Upon thorough review of the collective data, the Breast Cancer Prevention Collaborative Group (BCPCG) prioritized additional factors that might be included in the validation phase of a risk prediction model and gave a high priority score to free plasma estradiol levels. At present, routine measurement of plasma hormone levels is not recommended in the assessment of breast cancer risk.
One of the most widely studied factors in breast cancer etiology is the use of exogenous hormones in the form of oral contraceptives (OCs) and hormone replacement therapy (HRT).[23, 24] The overall evidence suggests an approximately 25% greater risk of breast cancer among current users of OCs. The risk appears to decrease with age and time since OC discontinuance. For OC users, risk returns to that of the average population risk about 10 years after cessation.
Data obtained from case-control and prospective cohort settings support an increased risk of breast cancer incidence and mortality with the use of postmenopausal HRT. Increased risk of breast cancer has been positively associated with length of exposure, with the greatest risk being observed for hormonally responsive lobular, mixed ductal-lobular, and tubular cancers. Risk is greater among women taking combination HRT than among those taking estrogen-only formulations.
In the Women’s Health Initiative (WHI) trial, the incidence of invasive breast cancer was 26% higher in women randomly assigned to combination HRT than in those assigned to placebo. In contrast, the use of estrogen (conjugated equine estrogen) alone in women who had undergone hysterectomy was associated with a 23% (but not significant) decrease in breast cancer risk in comparison with placebo at initial reporting.
On extended follow-up (median, 11.8 years), estrogen-only therapy for 5-9 years in women with hysterectomy was associated with a significant 23% reduction in the annual incidence of invasive breast cancer (0.27%; placebo, 0.35%). Fewer women died of breast cancer in the estrogen-only arm. These findings contrast with those reported from large observational case-control and prospective cohort studies, where estrogen alone was associated with increased risk (though the increase was consistently less than that associated with combined HRT use).
To aid the medical community in the application of HRT, a number of agencies and groups have published recommendations for HRT use in the treatment of menopause and associated bone loss. At present, HRT is not recommended for prevention of cardiovascular disease or dementia or, more generally, for long-term use to prevent disease.
Recommendations differ slightly by agency and by country. US and non-US evidence-based treatment recommendations can be found at the National Guidelines Clearinghouse Web site.
When prescribing HRT, the clinician should provide a discussion of the most current evidence and an assessment of the potential benefit and harm to the patient. Because of the known risk of endometrial cancer with estrogen-only formulations, the US Food and Drug Administration (FDA) currently advises the use of estrogen-plus-progesterone HRT for the management of menopausal symptoms in women with an intact uterus tailored to the individual patient, at the lowest effective dose for the shortest time needed to abate symptoms.
There are currently no formal guidelines for the use of HRT in women at high risk for breast cancer (ie, women with a family history of breast cancer, a personal history of breast cancer, or benign breast disease). Only a few studies have evaluated the effect of HRT after a diagnosis of breast cancer. The largest of these, the HABITS (Hormonal replacement therapy After Breast cancer—is IT Safe?) study was stopped early because unacceptable rates of breast cancer recurrence and contralateral disease with 2 years of HRT use (hazard ratio, 3.5).
In another randomized clinical trial, no increase in the risk of breast cancer recurrences was observed in women at a median follow up of 4.1 years. Use of progesterone-containing HRT was limited by intermittent use, with continuous exposure avoided.
Combination formulations containing estrogen plus progesterone are contraindicated in women with a prior history of invasive disease, a history of ductal or lobular carcinoma in situ, or a strong family history of breast cancer. This recommendation poses a significant challenge when confronted with a patient suffering severe menopausal symptoms.
Many new treatments for menopausal symptoms have been suggested (eg, clonidine, venlafaxine, gabapentin, and combination venlafaxine plus gabapentin). To date, no randomized clinical trials among women at increased risk of breast cancer or women with a history of breast cancer have assessed the overall efficacy or risks associated with these treatments. Use of these agents is controversial and should target the severity of menopausal symptoms.
Other hormone-based approaches (eg, low-dose vaginal estrogen for vaginal and urinary symptoms, including dyspareunia) are generally considered to be safer, particularly in patients receiving SERMs. However, these agents may also carry a slight increased risk, in that they are capable of raising estradiol levels, at least transiently, depending on the dose and frequency of administration. Little evidence supports the benefit of commonly used dietary isoflavones, black cohosh, or vitamin E.
Prior breast health history
A history of breast cancer is associated with a 3- to 4-fold increased risk of a second primary cancer in the contralateral breast.[32, 33, 34] The presence of any premalignant ductal carcinoma in situ (DCIS) or LCIS confers an 8- to 10-fold increase in the risk of developing breast cancer in women who harbor untreated preinvasive lesions.[35, 36]
A history of breast biopsy that is positive for hyperplasia, fibroadenoma with complex features, sclerosing adenosis, and solitary papilloma have been associated with a modest (1.5- to 2-fold) increase in breast cancer risk.[35, 36] In contrast, any diagnosis of atypical hyperplasia that is ductal or lobular in nature, especially in a woman under the age of 45 years, carries a 4- to 5-fold increased risk of breast cancer, with the increase rising to 8- to 10-fold among women with multiple foci of atypia or calcifications in the breast.
Benign breast lesions, including fibrocystic disease such as fibrocystic change without proliferative breast disease or fibroadenoma, have not been associated with increased risk.
Lifestyle risk factors
The wide variability of breast cancer incidence around the world (eg, the nearly 5-fold difference between Eastern Africa and Western Europe) has long been attributed to differences in dietary intake and reproductive patterns.[39, 40, 41, 42] In general, rates differ according to the level of industrial development: there are more than 80 cases per 100,000 in developed countries, compared with fewer than 40 per 100,000 in less developed countries.
As with cancers of the colon and prostate, diets that are rich in grains, fruits, and vegetables; low in saturated fats; low in energy (calories); and low in alcohol—the more common pattern in less industrialized countries—are thought to be protective against breast cancer.
Increased risk of postmenopausal breast cancer has been consistently associated with the following:
Adult weight gain of 20-25 kg above body weight at age 18 [44, 45]
Western dietary pattern (high energy content in the form of animal fats and refined carbohydrates)
Regular, moderate consumption of alcohol (3-5 alcoholic beverages per week)
The Western lifestyle (ie, chronic excess energy intake from meat, fat, and carbohydrates and lack of exercise) strongly correlates with development of the following:
Obesity, particularly abdominal obesity
Higher production and availability of insulinlike growth factor (IGF)-1
Increased levels of endogenous sex hormones through suppression of sex hormone–binding globulin [46, 47]
Studies of dietary fat, total energy, and meat intake levels have largely been inconsistent in population studies of adult women with regard to risk of breast cancer. In contrast, epidemiologic studies have more consistently found a positive relation between breast cancer risk and early-life exposures such as diet, obesity, and body size (including height).[48, 49, 50] The mechanism of this relation is unknown.
Environmental risk factors
A number of environmental exposures have been investigated in relation to breast cancer risk in humans, including the following[51, 52, 53, 54] :
Tobacco smoke (both active and passive exposure)
Dietary (eg, charred and processed meats)
Environmental carcinogens (eg, exposure to pesticides, radiation, and environmental and dietary estrogens)
Of these environmental exposures, only high doses of ionizing radiation to the chest area, particularly during puberty, have been unequivocally linked with an increased risk of breast cancer in adulthood.[54, 55] Because of the strong association between ionizing radiation exposure and breast cancer risk, medical diagnostic procedures are performed in such a way as to minimize exposure to the chest area, particularly during adolescence.
Women with a history of radiation exposure to the chest area should be examined and counseled regarding their risk of breast cancer on the basis of the timing and dose of the previous exposure. A patient treated for Hodgkin lymphoma with Mantel radiation that includes the breasts in the radiation field has a 5-fold higher risk of developing breast cancer. This risk increases markedly for women treated during adolescence ; evidence suggests that cumulative risk increases with age as a function of age of exposure and type of therapy.
Current evidence does not support a significant and reproducible link between other environmental exposures and breast cancer risk. Thus, a number of factors remain suspect but unproven.
United States statistics
In the United States, approximately 231,840 new cases of female invasive breast cancer are predicted to occur in 2015, along with 2350 cases in men. Among US women in 2015, in addition to invasive breast cancer, 60,290 new cases of in situ breast cancer are expected to occur; approximately 83% of these cases are expected to be DCIS, and 12% are expected to be LCIS.
The incidence of breast cancer in the United States increased rapidly from 1980 to 1987, largely as a consequence of the widespread use of mammography screening, which led to increased detection of asymptomatic small breast tumors. After 1987, the increase in overall rates of invasive breast cancers slowed significantly, specifically among white women aged 50 years or older.
Incidence over this period of time varied dramatically by histologic type. Common ductal carcinomas increased modestly from 1987 to 1999, whereas invasive lobular and mixed ductal-lobular carcinomas increased dramatically during this time period. For women under the age of 50, breast cancer rates have remained stable since the middle to late 1980s. Rates of DCIS have stabilized since 2000.
Whereas a decline in invasive breast cancer rates was evident as early as 1999, rates decreased dramatically in women aged 50 years or older between 2001 and 2004. During this same period, no significant change was observed in the incidence of ER-negative cancers or cancers in women younger than 50 years. The decline in rates from 2001 to 2004 was greatest between 2002 and 2003 and was limited to non-Hispanic whites.[60, 61, 62, 63]
The reason for the decline has been extensively debated. Breast cancer rates decreased significantly after the reports from the Million Women Study and the Women’s Health Initiative showing higher numbers of breast cancers in women using combination HRT with estrogen and progestin for menopausal symptoms. The near-immediate decrease in the use of combination HRT for that purpose has been widely accepted as a primary explanation for the decrease in breast cancer rates.
However, Jemal and Li argued that the decline in breast cancer incidence started earlier than the reduction in combination HRT use and that the decline is due in part to a “saturation” in mammographic screening mammography that produced a plateau in incidence when such screening stabilized in the late 1990s.[58, 61] Saturation of the population would be predicted to reduce the pool of undiagnosed or prevalent cases.
For women aged 69 years or older, breast cancer rates started to decline as early as 1998, when screening first showed a plateau. This observation is consistent with the prediction that if widespread screening and earlier detection are effective, they should result in a peak incidence among women during the sixth and seventh decades of life, followed by a decline. This is exactly the pattern now being reported for screened populations.
The second observation noted by Jemal et al was that despite evidence for a plateau effect, screening saturation alone could not explain the dramatic declines or the pattern of decline. The decline in incidence was observed only for ER-positive tumors and not for ER-negative ones; these findings support the competing hypothesis that exposure to HRT as estrogen in combination with synthetic progesterone promoted the growth of undetected tumors.
Under this scenario, withdrawal of combination HRT at the population level may have resulted in regression or a slowing of tumor growth. The latter, it has been argued, would result in a delay in detection. Overall, incidence figures from 2005-2009, for which the most recent data are currently available, suggest that overall new breast cancer case rates have remained fairly stable since the initial drop.
It is notable, however, that the annual percentage change from 2005 to 2009 increased in women aged 65-74 years by 2.7% during this period, rates that parallel 2001 incidence figures for this age group. This rise occurred in spite of very low use of HRT by this population and suggests that the drop in combination HRT use immediately after 2002 may not have resulted in a sustained decrease in new breast cancer cases.
At present, it is unclear whether decreased use of combination HRT has resulted in a sustained reduction in the incidence of breast cancer at the population level or has shifted the age at which preexisting disease would become detectable. Longer-term follow-up of post-2002 trends in relation to combination HRT use are needed to address this question.
The final decades of the 20th century saw worldwide increases in the incidence of breast cancer, with the highest rates reported in Westernized countries. Reasons for this trend are largely attributed to introduction of screening mammography. Changes in reproductive patterns—particularly fewer children and later age at first birth—may also have played a role, as may changes in lifestyle factors, including the following:
Western dietary patterns
Decreased physical activity
Rising obesity rates
More widespread use of exogenous hormones for contraception and treatment of menopausal symptoms
The beginning of the 21st century saw a dramatic decrease in breast cancer incidence in a number of Westernized countries (eg, the United Kingdom, France, and Australia). These decreases paralleled those noted in the United States and reflected similar patterns of mammography screening and decreased use of combination HRT.
In 2008, there were an estimated 1.38 million new cases of invasive breast cancer worldwide. The 2008 incidence of female breast cancer ranged from 19.3 cases per 100,000 in Eastern Africa to 89.9 cases per 100,000 in Western Europe.
With early detection and significant advances in treatment, death rates from breast cancer have been decreasing over the past 25 years in North America and parts of Europe. In many African and Asian countries (eg, Uganda, South Korea, and India), however, breast cancer death rates are rising.
The incidence rate of breast cancer increases with age, from 1.5 cases per 100,000 in women 20-24 years of age to a peak of 421.3 cases per 100,000 in women 75-79 years of age; 95% of new cases occur in women aged 40 years or older. The median age of women at the time of breast cancer diagnosis is 61 years.
Rates of in situ breast cancer stabilized among women 50 years and older in the late 1990s; this is consistent with the proposed effects of screening saturation. However, the incidence of in situ breast cancer continues to increase in younger women.
Race- and ethnicity-related demographics
In the United States, the incidence of breast cancer is higher in non-Hispanic whites than in women of other racial and ethnic groups. Among women younger than 40 years, African Americans have a higher incidence. In addition, a larger proportion of African-American women are diagnosed with larger, advanced-stage tumors (>5 cm) and are more likely to die of breast cancer at every age.
According to the American Cancer Society (ACS), breast cancer rates among women from various racial and ethnic groups are as follows :
Non-Hispanic white: 125.4/100,000
African American: 116.1/100,000
American Indian/Alaska Native: 89.2/100,000
Asian American/Pacific Islander: 84.9/100,000
According to the ACS, death rates from breast cancer among women from various racial and ethnic groups are as follows:
Non-Hispanic white: 23.9/100,000
African American: 32.4/100,000
American Indian/Alaska Native: 17.6/100,000
Asian American/Pacific Islander: 12.2/100,000
Breast cancer death rates among women in most racial and ethnic groups in the US have been declining since the early 1990s, except in American Indian and Alaska Native populations, among whom rates have remained stable.
Death rates from breast cancer in the United States have decreased steadily in women since 1990. Breast cancer mortality fell by 24% between 1990 and 2000 for women aged 30-79 years. The largest decrease in mortality has been seen in women younger than 50 years (3.3% per year) compared with those aged 50 years and older (2.0% per year).
The decrease in breast cancer death rates is thought to represent progress in both earlier detection and improved treatment modalities. The 2015 estimates are 40,730 expected breast cancer deaths (40,290 in women, 440 in men).
Prognostic and predictive factors
Numerous prognostic and predictive factors for breast cancer have been identified by the College of American Pathologists (CAP) to guide the clinical management of women with breast cancer. Breast cancer prognostic factors include the following:
Axillary lymph node status
Histologic subtypes (eg, tubular, mucinous [colloid], or papillary)
Response to neoadjuvant therapy
HER2 gene amplification or overexpression
Cancerous involvement of the lymph nodes in the axilla is an indication of the likelihood that the breast cancer has spread to other organs. Survival and recurrence are independent of level of involvement but are directly related to the number of involved nodes.
Patients with node-negative disease have an overall 10-year survival rate of 70% and a 5-year recurrence rate of 19%. In patients with lymph nodes that are positive for cancer, the recurrence rates at 5 years are as follows:
One to three positive nodes – 30-40%
Four to nine positive nodes – 44-70%
≥10 positive nodes – 72-82%
Hormone receptor–positive tumors generally have a more indolent course and are responsive to hormone therapy. ER and PR assays are routinely performed on tumor material by pathologists; immunohistochemistry (IHC) is a semiquantitative technique that is observer- and antibody-dependent.
This prognostic information can guide physicians in making therapeutic decisions. Pathologic review of the tumor tissue for histologic grade, along with the determination of ER/PR status and HER2 status, is necessary for determining prognosis and treatment. Evaluation of lymph node involvement by means of sentinel lymph node biopsy or axillary lymph node dissection is generally necessary as well. (See the Staging section in this article as well as Medscape Reference article Breast Cancer Staging.)
In the past, HER2 overexpression was associated with a more aggressive tumor phenotype and a worse prognosis (higher recurrence rate and increased mortality), independent of other clinical features (eg, age, stage, and tumor grade), especially in patients who did not receive adjuvant chemotherapy. Prognosis has improved with the routine use of HER2-targeted therapies, which consist of the following:
Trastuzumab – Monoclonal antibody
Pertuzumab – Monoclonal antibody
Lapatinib – A small-molecule oral tyrosine kinase inhibitor
Trastuzumab-emtansine – An antibody-drug conjugate directed specifically to the HER2 receptor
HER2 status has also been shown to predict response to certain chemotherapeutic agents (eg, doxorubicin). Retrospectively analyzed results from clinical trials have shown that HER2-positive patients benefit from anthracycline-based regimens, perhaps because of the frequent coamplification of topoisomerase II with HER2. Preliminary data also suggest that HER2 positivity may predict response to and benefit from paclitaxel in the adjuvant setting. (See Breast Cancer and HER2.)
Prognosis by cancer type
DCIS is divided into comedo (ie, cribriform, micropapillary, and solid) and noncomedo subtypes, a division that provides additional prognostic information on the likelihood of progression or local recurrence. Generally, the prognosis is worse for comedo DCIS than for noncomedo DCIS (see Histology).
Approximately 10-20% of women with LCIS develop invasive breast cancer within 15 years after their LCIS diagnosis. Thus, LCIS is considered a biomarker of increased breast cancer risk.
Infiltrating ductal carcinoma is the most commonly diagnosed breast tumor and has a tendency to metastasize via lymphatic vessels. Like ductal carcinoma, infiltrating lobular carcinoma typically metastasizes to axillary lymph nodes first. However, it also has a tendency to be more multifocal. Nevertheless, its prognosis is comparable to that of ductal carcinoma.
Typical or classic medullary carcinomas are often associated with a good prognosis despite the unfavorable prognostic features associated with this type of breast cancer, including ER negativity, high tumor grade, and high proliferative rates. However, an analysis of 609 medullary breast cancer specimens from various stage I and II National Surgical Adjuvant Breast and Bowel Project (NSABP) protocols indicates that overall survival and prognosis are not as good as previously reported. Atypical medullary carcinomas also carry a poorer prognosis.
Overall, patients with mucinous carcinoma have an excellent prognosis, with better than 80% 10-year survival. Similarly, tubular carcinoma has a low incidence of lymph node involvement and a very high overall survival rate. Because of the favorable prognosis, these patients are often treated with only breast-conserving surgery and local radiation therapy.
Cystic papillary carcinoma has a low mitotic activity, which results in a more indolent course and a good prognosis. However, invasive micropapillary ductal carcinoma has a more aggressive phenotype, even though approximately 70% of cases are ER-positive. A retrospective review of 1400 cases of invasive carcinoma identified 83 cases (6%) with at least one component of invasive micropapillary ductal carcinoma.
Additionally, lymph node metastasis is frequently seen in this subtype (incidence, 70-90%), and the number of lymph nodes involved appears to correlate with survival.
For metaplastic breast cancer, the majority of published case series have demonstrated a worse prognosis than with infiltrating ductal carcinoma, even when adjusted for stage, with a 3-year overall survival rate of 48-71% and 3-year disease-free survival rate of 15-60%. In most case series, large tumor size and advanced stage have emerged as predictors of poor overall survival and prognosis. Nodal status does not appear to impact survival in metaplastic breast cancer.
Paget disease of the breast is associated with an underlying breast cancer in 75% of cases. Breast-conserving surgery can achieve satisfactory results, but at the risk of local recurrence. Poor prognostic factors include a palpable breast tumor, lymph node involvement, histologic type, and an age of less than 60 years. Paget disease with a palpable mass usually has an invasive component and a lower 5-year survival rate (20-60%). Those that do not have an underlying palpable mass have a higher 5-year survival rate (75-100%).[72, 73]
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar. 65(2):87-108. [Medline].
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb. 65(1):5-29. [Medline].
[Guideline] Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine RE, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001 Mar 1. 19(5):1539-69. [Medline].
Surveillance Epidemiology and End Results (SEER). SEER Stat Fact Sheets: Breast. Available at http://seer.cancer.gov/statfacts/html/breast.html#incidence-mortality. Accessed: July 30, 2015.
Jatoi I, Anderson WF, Rosenberg PS. Qualitative age-interactions in breast cancer: a tale of two diseases? doi: 10.1097/COC.0b013e3181844d1c. Am J Clin Oncol. 2008 Oct. 31(5):504-6. [Medline].
Parmigiani G, Chen S, Iversen ES Jr, Friebel TM, Finkelstein DM, Anton-Culver H, et al. Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med. 2007 Oct 2. 147(7):441-50. [Medline]. [Full Text].
Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005 Dec 15. 104(12):2807-16. [Medline].
Kelsey JL, Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health. 1996. 17:47-67. [Medline].
Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol. 2000 Nov 15. 152(10):950-64. [Medline].
Deligeoroglou E, Michailidis E, Creatsas G. Oral contraceptives and reproductive system cancer. Ann N Y Acad Sci. 2003 Nov. 997:199-208. [Medline].
Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004 Feb 4. 96(3):218-28. [Medline].
Pike MC, Pearce CL, Peters R, Cozen W, Wan P, Wu AH. Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil Steril. 2004 Jul. 82(1):186-95. [Medline].
Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst. 2006 Oct 4. 98(19):1406-15. [Medline].
Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011 May. 12(5):496-503. [Medline].
Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005 Nov 16. 97(22):1652-62. [Medline]. [Full Text].
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998 Sep 16. 90(18):1371-88. [Medline].
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006 Jun 21. 295(23):2727-41. [Medline].
Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002 Apr 17. 94(8):606-16. [Medline].
Santen RJ, Boyd NF, Chlebowski RT, Cummings S, Cuzick J, Dowsett M, et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer. 2007 Jun. 14(2):169-87. [Medline].
Endogenous Hormones and Breast Cancer Collaborative Group. Free estradiol and breast cancer risk in postmenopausal women: comparison of measured and calculated values. Cancer Epidemiol Biomarkers Prev. 2003 Dec. 12(12):1457-61. [Medline].
Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002 Jun 27. 346(26):2025-32. [Medline].
Garbe E, Levesque L, Suissa S. Variability of breast cancer risk in observational studies of hormone replacement therapy: a meta-regression analysis. Maturitas. 2004 Mar 15. 47(3):175-83. [Medline].
Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol. 2006 Nov. 7(11):910-8. [Medline].
Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000 Jan 26. 283(4):485-91. [Medline].
Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012 May. 13(5):476-86. [Medline]. [Full Text].
Speroff L. The Million Women Study and breast cancer. Maturitas. 2003 Sep 25. 46(1):1-6. [Medline].
Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. Lancet. 2004 Feb 7. 363(9407):453-5. [Medline].
Loprinzi CL, Michalak JC, Quella SK, O'Fallon JR, Hatfield AK, Nelimark RA, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994 Aug 11. 331(6):347-52. [Medline].
Bordeleau L, Pritchard K, Goodwin P, Loprinzi C. Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. Clin Ther. 2007 Feb. 29(2):230-41. [Medline].
Page DL, Jensen RA. Evaluation and management of high risk and premalignant lesions of the breast. World J Surg. 1994 Jan-Feb. 18(1):32-8. [Medline].
Kollias J, Ellis IO, Elston CW, Blamey RW. Clinical and histological predictors of contralateral breast cancer. Eur J Surg Oncol. 1999 Dec. 25(6):584-9. [Medline].
Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD Jr, Simpson JF. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003 Jan 11. 361(9352):125-9. [Medline].
Page DL. Breast lesions, pathology and cancer risk. Breast J. 2004 Jan-Feb. 10 Suppl 1:S3-4. [Medline].
Ashbeck EL, Rosenberg RD, Stauber PM, Key CR. Benign breast biopsy diagnosis and subsequent risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2007 Mar. 16(3):467-72. [Medline].
Degnim AC, Visscher DW, Berman HK, Frost MH, Sellers TA, Vierkant RA, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol. 2007 Jul 1. 25(19):2671-7. [Medline].
Dupont WD, Page DL, Parl FF, Vnencak-Jones CL, Plummer WD Jr, Rados MS, et al. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med. 1994 Jul 7. 331(1):10-5. [Medline].
Henderson BE, Bernstein L. The international variation in breast cancer rates: an epidemiological assessment. Breast Cancer Res Treat. 1991 May. 18 Suppl 1:S11-7. [Medline].
Kaaks R. Nutrition, hormones, and breast cancer: is insulin the missing link?. Cancer Causes Control. 1996 Nov. 7(6):605-25. [Medline].
Stoll BA. Breast cancer and the western diet: role of fatty acids and antioxidant vitamins. Eur J Cancer. 1998 Nov. 34(12):1852-6. [Medline].
Holmes MD, Liu S, Hankinson SE, Colditz GA, Hunter DJ, Willett WC. Dietary carbohydrates, fiber, and breast cancer risk. Am J Epidemiol. 2004 Apr 15. 159(8):732-9. [Medline].
Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006 Jul 12. 296(2):193-201. [Medline].
Han D, Nie J, Bonner MR, McCann SE, Muti P, Trevisan M, et al. Lifetime adult weight gain, central adiposity, and the risk of pre- and postmenopausal breast cancer in the Western New York exposures and breast cancer study. Int J Cancer. 2006 Dec 15. 119(12):2931-7. [Medline].
Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. Novartis Found Symp. 2004. 262:247-60; discussion 260-68. [Medline].
Lukanova A, Lundin E, Zeleniuch-Jacquotte A, Muti P, Mure A, Rinaldi S, et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol. 2004 Feb. 150(2):161-71. [Medline].
Baer HJ, Colditz GA, Rosner B, Michels KB, Rich-Edwards JW, Hunter DJ, et al. Body fatness during childhood and adolescence and incidence of breast cancer in premenopausal women: a prospective cohort study. Breast Cancer Res. 2005. 7(3):R314-25. [Medline]. [Full Text].
Ruder EH, Dorgan JF, Kranz S, Kris-Etherton PM, Hartman TJ. Examining breast cancer growth and lifestyle risk factors: early life, childhood, and adolescence. Clin Breast Cancer. 2008 Aug. 8(4):334-42. [Medline]. [Full Text].
Fuemmeler BF, Pendzich MK, Tercyak KP. Weight, dietary behavior, and physical activity in childhood and adolescence: implications for adult cancer risk. Obes Facts. 2009. 2(3):179-86. [Medline]. [Full Text].
Laden F, Hunter DJ. Environmental risk factors and female breast cancer. Annu Rev Public Health. 1998. 19:101-23. [Medline].
Coyle YM. The effect of environment on breast cancer risk. Breast Cancer Res Treat. 2004 Apr. 84(3):273-88. [Medline].
Gammon MD, Eng SM, Teitelbaum SL, Britton JA, Kabat GC, Hatch M, et al. Environmental tobacco smoke and breast cancer incidence. Environ Res. 2004 Oct. 96(2):176-85. [Medline].
Smith-Bindman R. Environmental causes of breast cancer and radiation from medical imaging: findings from the Institute of Medicine report. Arch Intern Med. 2012 Jul 9. 172(13):1023-7. [Medline].
Carmichael A, Sami AS, Dixon JM. Breast cancer risk among the survivors of atomic bomb and patients exposed to therapeutic ionising radiation. Eur J Surg Oncol. 2003 Jun. 29(5):475-9. [Medline].
Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev. 2000 Aug. 26(4):291-302. [Medline].
Hill DA, Gilbert E, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood. 2005 Nov 15. 106(10):3358-65. [Medline]. [Full Text].
Li CI, Daling JR. Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev. 2007 Dec. 16(12):2773-80. [Medline].
American Cancer Society. Breast Cancer Facts & Figures 2011-2012. Available at http://www.cancer.org/Research/CancerFactsFigures/BreastCancerFactsFigures/breast-cancer-facts-and-figures-2011-2012. Accessed: June 10, 2013.
Glass AG, Lacey JV Jr, Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007 Aug 1. 99(15):1152-61. [Medline].
Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007 Apr 19. 356(16):1670-4. [Medline].
Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat. 2008 Feb. 107(3):427-30. [Medline].
Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003 Aug 9. 362(9382):419-27. [Medline].
Anderson WF, Reiner AS, Matsuno RK, Pfeiffer RM. Shifting breast cancer trends in the United States. J Clin Oncol. 2007 Sep 1. 25(25):3923-9. [Medline].
Evidence-based assessment of the impact of the WHI on women’s health. doi: 10.3109/13697137.2012.655564. Burger HG, MacLennan AH, Huang KE, Castelo-Branco C. Climacteric. 2012 Jun. 15(3):281-7.
[Guideline] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer, v.3.2014. Available at http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed: July 11, 2014.
Baselga J, Seidman AD, Rosen PP, Norton L. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Williston Park). 1997 Mar. 11(3 Suppl 2):43-8. [Medline].
Nassar H, Wallis T, Andea A, Dey J, Adsay V, Visscher D. Clinicopathologic analysis of invasive micropapillary differentiation in breast carcinoma. Mod Pathol. 2001 Sep. 14(9):836-41. [Medline].
Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol. 1999 Apr. 10(4):413-9. [Medline].
Chao TC, Wang CS, Chen SC, Chen MF. Metaplastic carcinomas of the breast. J Surg Oncol. 1999 Aug. 71(4):220-5. [Medline].
Chaudary MA, Millis RR, Lane EB, Miller NA. Paget's disease of the nipple: a ten year review including clinical, pathological, and immunohistochemical findings. Breast Cancer Res Treat. 1986. 8(2):139-46. [Medline].
Kollmorgen DR, Varanasi JS, Edge SB, Carson WE 3rd. Paget’s disease of the breast: a 33-year experience. J Am Coll Surg. 1998 Aug. 187(2):171-7.
Brooks M. BRCA Testing Update: 'Do This, Don't Do That.'. Medscape Medical News. Available at http://www.medscape.com/viewarticle/818267. Accessed: January 6, 2014.
[Guideline] Moyer VA. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2013 Dec 24. [Medline].
Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005 Oct 27. 353(17):1784-92. [Medline].
Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. Lancet Oncol. 2015 Jul 20. [Medline].
Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014 Feb 11. 348:g366. [Medline]. [Full Text].
Chustecka Z. FDA Warning on Nipple Aspirate Test as Breast Cancer Screen. Medscape Medical News. Dec 13 2013. [Full Text].
Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002 Mar 16. 359(9310):909-19. [Medline].
Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet. 2003 Apr 26. 361(9367):1405-10. [Medline].
Noble M, Bruening W, Uhl S, Schoelles K. Computer-aided detection mammography for breast cancer screening: systematic review and meta-analysis. Arch Gynecol Obstet. 2009 Jun. 279(6):881-90. [Medline].
Barclay L. Digital mammography: direct outperforms computed radiography. Medscape Medical News. May 14, 2013. [Full Text].
Chiarelli AM, Edwards SA, Prummel MV, Muradali D, Majpruz V, Done SJ, et al. Digital compared with screen-film mammography: performance measures in concurrent cohorts within an organized breast screening program. Radiology. 2013 May 14. [Medline].
Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002 Sep 3. 137(5 Part 1):347-60. [Medline].
Ward E, Jemal A, Thun M. Regarding "Increase in breast cancer incidence in middle-aged women during the 1990s". Ann Epidemiol. 2005 Jul. 15(6):424-5; author reply 426-7. [Medline].
US Preventive Services Task Force. Screening for Breast Cancer. Available at http://www.uspreventiveservicestaskforce.org/uspstf/uspsbrca.htm. Accessed: May 23, 2013.
Smith RA, Saslow D, Sawyer KA, Burke W, Costanza ME, Evans WP 3rd, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin. 2003 May-Jun. 53(3):141-69. [Medline].
[Guideline] Oeffinger KC, Fontham ETH, Etzioni R, et al. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA. October 20, 2015. 314:[Full Text].
[Guideline] Wilt TJ, Harris RP, Qaseem A, et al. Screening for Cancer: Advice for High-Value Care From the American College of Physicians. Ann Intern Med. 2015. 162:718-725. [Full Text].
Kerlikowske K, Zhu W, Tosteson A, et al. Identifying Women With Dense Breasts at High Risk for Interval Cancer: A Cohort Study. Ann Intern Med. 2015. 162:673-681.
Taillefer R. Clinical applications of 99mTc-sestamibi scintimammography. Semin Nucl Med. 2005 Apr. 35(2):100-15. [Medline].
Chen AC, Paulino AC, Schwartz MR, Rodriguez AA, Bass BL, Chang JC, et al. Prognostic markers for invasive micropapillary carcinoma of the breast: a population-based analysis. Clin Breast Cancer. 2013 Apr. 13(2):133-9. [Medline].
[Guideline] Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014 May 1. 32(13):1365-83. [Medline].
[Guideline] National Comprehensive Cancer Network Practice Guidelines. Invasive Breast Cancer. 2009. (Registered Users Only). Available at http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf.
[Guideline] Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007 Jan 1. 25(1):118-45. [Medline].
Tang G, Cuzick J, Costantino JP, Dowsett M, Forbes JF, Crager M, et al. Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol. 2011 Nov 20. 29(33):4365-72. [Medline]. [Full Text].
Johnson K. For node-positive breast cancer, axillary radiation is best. Medscape Medical News. June 6, 2013. [Full Text].
Haviland JS, Owen JR, Dewar JA, et al, on behalf of the START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013 Sep 18. [Medline].
Mulcahy N. Ten-year data confirm shorter radiotherapy best for breast cancer. Medscape Medical News. September 19, 2013. [Full Text].
Chustecka Z. New guideline on lumpectomy margins should reduce re-excision. Medscape Medical News. February 11, 2014. [Full Text].
[Guideline] Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, et al. Society of Surgical Oncology-American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. Int J Radiat Oncol Biol Phys. 2014 Mar 1. 88(3):553-64. [Medline].
American Society of Breast Surgeons. Consensus Statement for Accelerated Partial Breast Irradiation. Available at https://www.breastsurgeons.org/statements/PDF_Statements/APBI.pdf. Accessed: May 24, 2013.
Mulcahy N. Is whole-breast radiation better in older women?. Medscape Medical News. February 6, 2014. [Full Text].
Smith GL, Jiang J, Buchholz TA, Xu Y, Hoffman KE, Giordano SH, et al. Benefit of adjuvant brachytherapy versus external beam radiation for early breast cancer: impact of patient stratification on breast preservation. Int J Radiat Oncol Biol Phys. 2014 Feb 1. 88(2):274-84. [Medline].
Kuske RR, Young SS. Breast brachytherapy versus whole-breast irradiation: reported differences may be statistically significant but clinically trivial. Int J Radiat Oncol Biol Phys. 2014 Feb 1. 88(2):266-8. [Medline].
Mulcahy N. One-Stop' Radiotherapy Saves Time With Breast Cancer. M. Available at http://www.medscape.com/viewarticle/814157. Accessed: November 21, 2013.
Mulcahy N. One-Stop' Radiotherapy Saves Time With Breast Cancer. Medscape Medical News. Available at http://www.medscape.com/viewarticle/814157. Accessed: November 21, 2013.
Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2013 Nov 8. [Medline].
Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013 Nov 8. [Medline].
Ebctcg Early Breast Cancer Trialists' Collaborative Group. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014 Mar 19. [Medline].
Chustecka Z. Radiotherapy for Early Breast Cancer and 1 to 3 Positive Nodes. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/822213. Accessed: March 24, 2014.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015 Jul 23. [Medline]. [Full Text].
Mulcahy N. Large DCIS Study Is 'Compelling Case' for Change. Medscape Medical News. Available at http://www.medscape.com/viewarticle/849878?nlid=87391_2203&src=wnl_edit_medn_honc&uac=72886PK&spon=7&impID=799971&faf=1. August 20, 2015; Accessed: August 30, 2015.
Esserman L, Yau C. Rethinking the Standard for Ductal Carcinoma In Situ Treatment. JAMA Oncol. 2015 Aug 20. [Medline].
Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012 Apr 20. 30(12):1268-73. [Medline]. [Full Text].
Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, et al. Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. J Clin Oncol. 2013 Sep 1. 31(25):3091-3099. [Medline].
Nelson R. Tamoxifen Cuts Risk for Breast Cancer in BRCA Carriers. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/809174. Accessed: September 1, 2013.
ClinicalTrials.gov. Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy. Available at https://clinicaltrials.gov/ct2/show/NCT00053898. Accessed: August 30, 2015.
Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Jan. 13(1):25-32. [Medline].
[Guideline] Barclay L. New ASCO Guidelines Address HER2-Positive Breast Cancer. Medscape Medical News. May 7 2014. [Full Text].
[Guideline] Giordano SH, Temin S, Kirshner JJ, et al. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014 May 5. [Medline].
Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006 May 1. 24(13):2019-27. [Medline].
[Guideline] Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, et al. Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014 Sep 2. [Medline].
Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012 Aug 2. 367(5):435-44. [Medline]. [Full Text].
O'Shaughnessy J. Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience. Oncology (Williston Park). 2003 Dec. 17(12 Suppl 14):15-21. [Medline].
Perez EA, Hillman DW, Stella PJ, Krook JE, Hartmann LC, Fitch TR, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer. 2000 Jan 1. 88(1):124-31. [Medline].
Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006 Dec 1. 24(34):5381-7. [Medline].
Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan. 16(1):25-35. [Medline].
Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 Dec 27. 357(26):2666-76. [Medline].
O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002 Jun 15. 20(12):2812-23. [Medline].
Biganzoli L, Martin M, Twelves C. Moving forward with capecitabine: a glimpse of the future. Oncologist. 2002. 7 Suppl 6:29-35. [Medline].
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15. 344(11):783-92. [Medline].
Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005 Jul 1. 23(19):4265-74. [Medline].
Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15. 19(10):2722-30. [Medline].
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006 Dec 28. 355(26):2733-43. [Medline].
Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008 Aug 20. 26(24):3950-7. [Medline].
Chustecka Z. Novel Drug Approved for Breast Cancer: Palbociclib (Ibrance). Medscape Medical News. Available at http://www.medscape.com/viewarticle/839171. Accessed: March 20, 2015.
Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan. 16(1):25-35. [Medline].
[Guideline] Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, et al. Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2013 Jul 8. [Medline].
Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011 Jun 23. 364(25):2381-91. [Medline].
Busko M. Regular Echo Exams Warranted to Detect Radiation-Induced Heart Disease. Medscape Medical News. Available at http://www.medscape.com/viewarticle/808213. Accessed: July 30, 2013.
Lancellotti P, Nkomo VT, Badano LP, Bergler J, Bogaert J, Davin L, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging. 2013 Aug. 14(8):721-40. [Medline].
[Guideline] Greenlee H, Balneaves L, Carlson M, et al. Clinical Practice Guidelines on the Use of Integrative Therapies as Supportive Care in Patients Treated for Breast Cancer. J Natl Cancer Inst. 2014. 50:346-358. [Full Text].
US Food & Drug Administration. FDA Commissioner announces Avastin decision: Drug not shown to be safe and effective in breast cancer patients. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280536.htm. Accessed: June 10, 2013.
Nelson R. Capecitabine Linked to Potentially Fatal Skin Reactions. Medscape Medical News. Dec 3 2012. [Full Text].
Ellence [package insert]. New York, NY: Pfizer. Feb 2007.
Xeloda [package insert]. South San Francisco, Calif: Genentech. November 2009.
Herceptin [package insert]. South San Francisco, Calif: Genentech. October 2010.
Tykerb [package insert]. Research Triangle Park, NC: GlaxoSmithKline. January 2010.
Femara [package insert]. East Hanover, NJ: Novartis. April 2010.
Ruiter R, Bijl MJ, van Schaik RH, Berns EM, Hofman A, Coebergh JW, et al. CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics. 2010 Oct. 11(10):1367-75. [Medline].
Fareston [package insert]. Memphis, Tenn: GTX. December 2004.
Chustecka Z. New Guidelines on Chemoprevention for Breast Cancer. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/811553. Accessed: October 7, 2013.
[Guideline] Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014 Feb 11. 348:g226. [Medline]. [Full Text].
Michels KB. Contralateral mastectomy for women with hereditary breast cancer. BMJ. 2014 Feb 11. 348:g1379. [Medline].
Moore HCF, Unger JM, Phillips KA, Boyle FM, Hitre E, Porter DJ, et al. Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international intergroup trial of SWOG, IBCSG, ECOG, and CALGB. Abstract LBA505. Presented May 31, 2014, at the 2014 annual meeting of the American Society of Clinical Oncology. American Society of Clinical Oncology. Available at http://meetinglibrary.asco.org/content/129172-144. Accessed: June 9, 2014.
Moyer VA. Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2013 Sep 24. [Medline].
Mulcahy N. ASCO adds oomph to breast cancer chemoprevention guide. Medscape Medical News. July 8, 2013. [Full Text].
Mulcahy N. Practice changing: drug preserves fertility during chemo. Medscape Medical News. May 30, 2014. [Full Text].
[Guideline] Nelson R. Double Mastectomy Boosts Survival in BRCA Mutation Carriers. Medscape Medical News. Feb 12 2014. [Full Text].
- Table 1. Accuracy of Breast Imaging Modalities
- Table 2. Grading System in Invasive Breast Cancer (Modified Bloom and Richardson)
- Table 3. Ductal Carcinoma in Situ Subtypes
- Table 4. TNM Staging System for Breast Cancer
- Table 5. Hormone Agents Used in Breast Cancer
- Table 6. Targeted Chemotherapy for Metastatic Breast Cancer
- Table 7. Combination Regimens for Metastatic Breast Cancer
- Table 5. Follow-up Recommendations for Breast Cancer Survivors
|Mammography||63-95% (>95% palpable, 50% impalpable, 83-92% in women older than 50 y; decreases to 35% in dense breasts)||14-90% (90% palpable)||10-50%
|Initial investigation for symptomatic breast in women older than 35 y and for screening; investigation of choice for microcalcification|
|Ultrasonography||68-97% palpable||74-94% palpable||92% (palpable)||Initial investigation for palpable lesions in women younger than 35 y|
|MRI||86-100%||21-97% (< 40% primary cancer)||52%||Scarred breast, implants, multifocal lesions, and borderline lesions for breast conservation; may be useful in screening high-risk women|
|Scintigraphy||76-95% palpable, 52-91% impalpable||62-94% (94% impalpable)||70-83% (83% palpable, 79% impalpable)||Lesions >1 cm and axilla assessment; may help predict drug resistance|
|PET||96% (90% axillary metastases)||100%||Axilla assessment, scarred breast, and multifocal lesions|
|MRI = magnetic resonance imaging; PET = positron emission tomography; PPV = positive predictive value.|
|1||> 2||> 3|
|A. Tubule formation||>75%||10-75%||< 10%|
|B. Mitotic count/HPF (microscope- and field-dependent)||< 7||7-12||>12|
|C. Nuclear size and pleomorphism||Near normal; little variation||Slightly enlarged; moderate variation||Markedly enlarged; marked variation|
|Grade I cancer if total score (A + B + C) is 3-5|
|Grade II cancer if total score (A + B + C) is 6 or 7|
|Grade III cancer if total score (A + B + C) is 8 or 9|
|HPF = high-power field.|
|Estrogen receptor||Often negative||Positive|
|DCIS = ductal carcinoma in situ.|
|Stage IIIC||Any T||N3||M0|
|Stage IV||Any T||Any N||M1|
|Agent||Dose and Schedule|
|Tamoxifen||20 mg PO every day|
|Anastrozole||1 mg PO every day|
|Letrozole||2.5 mg PO every day|
|Exemestane||25 mg PO every day|
|Fulvestrant||500 mg IM loading dose followed
by 250 mg IM every month
|Megestrol||40 mg PO 4 times a day|
|Tamoxifen||20 mg PO every day|
|Aromatase inhibitor + LHRH*|
|Leuprolide||7.5 mg IM depot q28d
22.5 mg IM q3mo
30 mg IM q4mo
|Goserelin||3.6 mg SC depot q28d
10.8 mg SC q3mo
|Megestrol||40 mg PO 4 times a day|
|*LHRH = luteinizing hormone–releasing hormone.|
|Drug||Class||Dose/Schedule||Overall Response Rate (ORR)||Toxicity|
|Capecitabine||Oral fluoro-pyrimidine||1250 mg/m²/d PO for 2 weeks with 1 wk off||30%||Rash, hand-foot syndrome,
|Docetaxel||Antimicrotubule||75-100 mg/m² IV q3wk
40 mg/m²/wk X IV for 6 wk with 2 wk off
skin reaction, mucositis,
and fluid retention
|45-60 mg/m² IV q3wk
20 mg/m² IV qwk (not to
exceed a cumulative dose
of 450-500 mg/m²)
vomiting, mucositis, diarrhea
|Anthracycline||20 mg/m² IV q2wk
35-40 mg/m² IV q4wk
|Less cardiotoxicity, neutropenia, alopecia, stomatitis, hand-foot
|Epirubicin||Anthracycline||90 mg/m² IV q3wk (not
to exceed cumulative dose
of 900 mg/m²)
|35-50%||Myelosuppression, mucositis, nausea, vomiting, cardiotoxicity|
|Gemcitabine||Antimetabolite||725 mg/m²/wk IV for 3 wk
then 1 wk off
IV X 2 then 1 wk off
vomiting, flulike syndrome,
|Nab-paclitaxel||Antimicrotubule||80-100 mg/m²/wk IV X 3 then 1 wk off
260 mg/m² IV q3wk
|Less neuropathy, and allergic reaction|
|Paclitaxel||Antimicrotubule||80 mg/m²/wk IV
175 mg/m² IV over 3 hours q3wk
neuropathy, allergic reaction
|Trastuzumab||Monoclonal antibody||4 mg/kg loading dose, then 2
mg/kg weekly or
loading dose, then 6 mg/kg
|10-15%||Fever, allergic reaction,
cardiotoxicity/congestive heart failure
|Pertuzumab||Monoclonal antibody||840 mg IV loading dose,
then 420 mg q3wk
Give with trastuzumab and docetaxel
|80.2% (objective response rate)||Fever, allergic reaction,
cardiotoxicity/congestive heart failure
|Palbociclib||CDK inhibitor||125 mg/day PO for 3 weeks with 1 wk off
Give with letrozole
|Data are not available for ORR
Mean PFS was 10.2 months in the letrozole group and 20.2 months for palbociclib plus letrozole group
|Neutropenia, leukopenia, thrombocytopenia, anemia, stomatitis|
|Vinorelbine||Vinca alkaloid||20 mg/m²/wk IV||35-45%||Myelosuppression, nausea/
vomiting, constipation, fatigue,
|Chemotherapy||Dose and Schedule||Cycle|
|1250 mg/m² bid days 1-14
75 mg/m² day 1
|Repeat cycle every 21 days
May decrease capecitabine dose
to 850-1000 mg/m² to reduce
|825 mg/m² bid days 1-14
175 mg/m² day 1
|Repeat cycle every 21 days|
|1000 mg/m² bid days 1-14
25 mg/m² days 1 and 8
|Repeat cycle every 21 days|
|1250 mg/m² days 1 and 8
175 mg/m² day 1
|Repeat cycle every 21 days|
|AUC of 6 day 1
200 mg/m² day 1
|Repeat cycle every 21 days|
|AUC of 6 day 1
75 mg/m² day 1
|Repeat cycle every 21 days|
|125 mg PO once daily days 1-21
2.5 mg PO once daily days 1-28
|Repeat cycle every 28 days|
|Paclitaxel||90 mg/m² day 1, 8, and 15||Repeat cycle every 28 days|
|HER2-positive metastatic breast cancer regimens|
|4 mg/kg loading dose then
2 mg/kg weekly
80 mg/m² IV weekly
|8 mg/kg loading dose then
6 mg/kg day 1
100 mg/m² IV day 1
|Repeat cycle every 21 days|
|4 mg/kg loading dose then
2 mg/kg weekly
25 mg/m² day 1 weekly
|1250 mg PO daily
2000 mg/m² daily days 1-14
|Repeat cycle every 21 days|
|Repeat cycle every 3 weeks|
|AUC = systemic exposure.
References for chemotherapy regimens: XT, XP, XN, HER2-positive metastatic breast cancer regimens[135, 136, 137, 138]
|History and physical examination||Year 1, every 3-4 mo
Year 2, every 4 mo
Year 3-5, every 6 mo
Year 6+, annually
|Year 1-3, every 3-6 mo
Year 4-5, every 6-12 mo
Year 6+, annually
|Breast self-examination||No recommendation||Counseled to perform monthly breast self-examination|
|Mammography||6 mo after post-BCS radiation therapy
|6 mo after definitive radiation therapy
Every 6-12 mo for surveillance of abnormalities
Annually if stability of abnormalities is achieved
|Pelvic examination||Annually, for women on tamoxifen
Annual exam if uterus present
|Regular gynecologic follow-up
Patients on tamoxifen should be advised to report any vaginal bleeding
|Routine blood tests||Not recommended||Not recommended|
|Imaging studies||Not recommended||Not recommended|
|Tumor marker testing||Not recommended||Not recommended|
|Women aged ≥65 years|
|Woman aged 60-64 years with ≥1 of the following:
1. Family history of osteoporosis
2. Low body weight
3. Prior nontraumatic fracture
4. Other risk factors (eg, smoking, sedentary lifestyle)
|Postmenopausal women on aromatase inhibitors|
|Premenopausal women who develop treatment related premature menopause|